New evidence for the use of abatacept in the treatment of interstitial lung disease (ILD) associated with RA has the potential to be practice changing, rheumatologists say. A multicentre observational study of 263 patients with RA-ILD has found stable or improved pulmonary function tests in ~90% of the patients who were treated with abatacept. Furthermore, ...
New evidence for abatacept in RA-ILD could be practice changing
By Nicola Garrett
28 Oct 2020